Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Qiagen ( (QGEN) ).
QIAGEN has disclosed an update on significant shareholdings after being notified by the Dutch financial regulator AFM of a new voting rights announcement involving Goldman Sachs Group Inc. The notification, published in the AFM register, details Goldman Sachs’ various direct and indirect positions in QIAGEN shares and related derivatives such as call options, convertible bonds, warrants and swaps, both with real and potential voting rights.
According to the filing, Goldman Sachs’ total holding in QIAGEN corresponds to 3.42% of the company’s capital and voting rights, largely through indirect and potential instruments managed by several Goldman Sachs entities. The disclosure clarifies the structure and scale of Goldman Sachs’ exposure to QIAGEN, providing investors with greater transparency on the shareholder base and potential influence of a major financial institution over the company’s stock.
The most recent analyst rating on (QGEN) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and diagnostics company whose shares are listed on major European exchanges as well as the NYSE and Swiss venues. The company operates in regulated markets and is followed closely by international institutional investors, reflecting its role in the global biotechnology and molecular diagnostics sector.
Average Trading Volume: 1,973,130
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.5B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.